Synthesis and multifaceted evaluation of novel AgCZ nanocomposite for targeted anti-angiogenic cancer therapy

Angiogenesis is the formation of blood vessels from the existing vasculature, which is important in the tumor growth where the metastatic spread, of cancer cells depends on an adequate supply of oxygen and nutrients and the removal of waste products. Targeting angiogenesis has emerged as a promising therapeutic strategy for cancer treatment. This study presents the synthesis and evaluation of a novel Ag-CeO₂-ZnO (AgCZ) nanocomposite designed to specifically inhibit angiogenesis for effective cancer therapy. The nanocomposite was synthesized via a glycine-assisted combustion method, and its physicochemical properties were meticulously characterized using advanced analytical techniques. The anti-angiogenesis potential of the AgCZ nanocomposite was vigorously explored through an assortment of in vitro investigations, with a particular interest in inhibiting agents like vascular endothelial growth factor (VEGF). In silico data from molecular docking studies were instrumental in elucidating the nanocomposite's primary reported mechanism of action, i.e., its strong VEGF target bond. Notably, the nanocomposite had selective cytotoxicity with different types of cancer cells and no sign of serious influence onto normal cells, reflecting great promise of the targeted cancer therapy. Not and importantly, nanocomposite was implemented in vitro studies to measure its anti-angiogenic as well as anti-tumor effect in biological models additionally. Our study highlights emerging developments in medicine and draws possible future paths. The use of AgCZ composite nanoparticle is one of the potential anticancer drug and alternative to the conventional medicine which appears to be safer and more effectual, but further research is needed to overcome current limitations in clinical translation.